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A key feature of chronic lymphocytic leukaemia (CLL) cells is overexpressed protein kinase CβII (PKCβII), 
an S/T kinase important in the pathogenesis of this and other B cell malignancies. The mechanisms 
contributing to enhanced transcription of the gene coding for PKCβII, PRKCB, in CLL cells remain poorly 
described, but could be important because of potential insight into how the phenotype of these cells is 
regulated. Here, we show that SP1 is the major driver of PKCβII expression in CLL cells where enhanced 
association of this transcription factor with the PRKCB promoter is likely because of the presence of 
histone marks permissive of gene activation. We also show how vascular endothelial growth factor 
(VEGF) regulates PRKCB promoter function in CLL cells, stimulating PKCβ gene transcription via increased 
association of SP1 and decreased association of STAT3. Taken together, these results are the first to 
demonstrate a clear role for SP1 in the up regulation of PKCβII expression in CLL cells, and the first to link 
SP1 with the pathogenesis of this and potentially other B cell malignancies where PKCβII is overexpressed.
Chronic lymphocytic leukaemia (CLL) is a common malignancy of mature B cells1,2. A distinctive feature of the 
malignant cells in this disease is overexpression of protein kinase Cβ II (PKCβ II)3, a classical PKC isoform that is 
involved in a wide variety of cellular processes4. PKCβ II is important to the pathophysiology of CLL cells because 
of its role in regulating B cell receptor (BCR) signalling5–8, and because it can enhance cell survival by activating 
Akt9 and phosphorylating Bcl2 at the mitochondrial membrane10. Finally, studies using the Tcl1 mouse model of 
CLL have shown that disease fails to develop when the gene encoding PKCβ II, PRKCB, is genetically deleted11.
In addition to CLL, overexpression of PKCβ II is also observed in B-lymphocyte malignancies such as dif-
fuse large B cell and mantle cell lymphoma12,13, and in epithelial tumours such as carcinoma of the colon14 and 
breast15. Indeed, like CLL, the development of colon cancer is intrinsically linked with overexpressed PKCβ II16,17. 
Therefore, understanding how expression of this protein is regulated may give insight into the pathogenesis and 
progression of CLL and other cancers.
The basal promoter region of PRKCB is characterised18,19 with early studies identifying binding sites for the 
transcription factors (TF) MITF20 and RUNX121. Experiments in more recent literature have demonstrated addi-
tional binding sites for SP122 as well as for STAT323. However, how these TFs contribute to overexpression of 
PRKCB in the malignant cells of CLL and other cancers is poorly described. Potential insight into this mechanism 
is provided by previous work from this Department showing PRKCB transcription can be induced in CLL cells by 
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VEGF-induced stimulation of PKCβ II activity24. This mechanism is also reportedly used in other cell systems25,26, 
and may be of particular importance to the pathogenesis of CLL because of the high levels of this cytokine present 
within tissues where expansion of the malignant clone takes place27,28.
In the present study we show SP1 is a major driver of PKCβ II overexpression in primary CLL cells. Enhanced 
gene transcription of PRKCB in CLL compared to normal B cells is likely the result of increased access of SP1 to 
the gene promoter region facilitated by the presence of permissive histone marks. We also find that STAT3 has 
a suppressive role for the activity of the PRKCB promoter in CLL cells and increased binding of STAT3 to this 
site is linked with decreased association of SP1. Treatment with VEGF causes a decrease in STAT3 binding to the 
PRKCB promoter and maintains elevated binding of SP1 during in vitro culture. Taken together, these results 
demonstrate a direct relationship between SP1 binding and PRKCB transcription, and further suggest that this TF 
is a contributor to the pathobiology of CLL and potentially other malignant cells where PKCβ II is overexpressed.
Results
SP1 mediates PRKCB transcription in CLL and MEC1. Our previous work showed that treatment of CLL 
cells with mithramycin, a drug that intercalates into G-C rich areas of DNA to inhibit SP1-mediated gene transcrip-
tion29,30, quantitatively reduces levels of PKCβ II mRNA without affecting cell viability24. Our present work confirms 
these data, and shows that PKCβ II mRNA levels in CLL cells are reduced in a concentration-dependent fashion by 
mithramycin (Fig. 1a). Likewise, mithramycin treatment of MEC1 cells, a B cell line derived from a CLL patient under-
going prolymphocytoid transformation31, showed similar concentration-dependent reduction in PKCβ II mRNA 
regardless of whether the cells were cultured under serum-free or serum-rich conditions (Supplementary Figure 1A). 
Because SP1 transcribes many genes involved in cell cycle32, the use of serum-free conditions to culture MEC1 cells 
rules out any effects imparted by potential interruption of the cell cycle by mithramycin. We observed that maximal 
reduction of PKCβ II mRNA levels in CLL and MEC1 cells was achieved using a concentration of 200 nM mithramycin 
(Fig. 1a and b, Supplementary Figure 1A). Taken together, these data show that MEC1 and CLL cells respond similarly 
to mithramycin, and suggest that the former cells can be used to model the behaviour of in-vitro cultured CLL cells.
To more directly examine the role of SP1 in the transcription of PRKCB we used siRNA. Figure 1c–e shows 
that reduction of SP1 mRNA and protein levels in CLL cells using specific siRNA results in a concomitant 
reduction of PKCβ II mRNA and protein expression. Similar reduction of SP1 and PKCβ II mRNA was observed 
using MEC1 cells, with optimal results being obtained using a mixture of SP1-specific siRNA oligonucleotides 
(Supplementary Figure 1B,C).
We next investigated the role of SP1 in driving PRKCB promoter function by luciferase assay whereby 500 bp 
of the proximal PRKCB promoter responsible for its basal activity was cloned upstream of the luciferase gene 
in a pGL3 plasmid (pGL3-pkcβ -0.5 kb)19,26. Figure 2a shows that presence of 200 nM mithramycin significantly 
reduces the level of luciferase activity in transfected MEC1 cells that were cultured under serum-free conditions. 
Reduction of SP1 expression with specific siRNA also blocked PRKCB promoter-driven expression of luciferase 
in MEC1 cells, whereas control siRNA or mock transfection had no effect (Fig. 2b). The PRKCB promoter con-
tains two binding motifs for SP1 at positions − 94 (site 1) and − 63 (site2)19. Loss of either or both of these motifs 
through site directed mutagenesis resulted in a complete loss of promoter function (Fig. 2c). This indicates that 
both SP1 motifs are essential for PRKCB basal promoter activity and supports previous reports demonstrating 
that synergistic binding of SP1 drives transcriptional activation in gene promoters33,34. Taken together, these 
results demonstrate a direct relationship between SP1 and PRKCB gene transcription, and shows that synergistic 
binding of SP1 is essential for PKCβ II expression in CLL cells.
SP1 binds more readily to the PRKCB promoter sequence in CLL than normal B cells. A direct 
role of SP1 in regulating PKCβ II expression was confirmed using chromatin immunoprecipitation (ChIP). We 
found that SP1 bound the PRKCB promoter in CLL cells, and that this binding was significantly enhanced com-
pared to that in normal B cells (Fig. 3a). In line with the ability of mithramycin to suppress PKCβ II expression in 
CLL cells, we also found that SP1 binding to the PRKCB promoter is disrupted in cells treated with this compound 
(Fig. 3b). Thus, SP1 binds the PRKCB promoter in CLL cells and its increased association is likely responsible for 
overexpression of the gene.
The PRKCB promoter sequence in CLL cells is unmethylated and contains higher levels of his-
tone marks permissive of gene activation. The PRKCB promoter is enriched with CpG islands and 
expression from this gene can potentially be affected by gene methylation19,22. To investigate whether this con-
tributes to enhanced binding of SP1 to PRKCB in CLL cells we performed experiments assessing the methylation 
status of the CpG island located near the SP1 binding sites of the promoter. We found that this region was virtually 
unmethylated and markedly similar between CLL and normal B cells (p = 0.84, Mann-Whitney U-test, Table 1).
Histone H3 hyperacetylation (H3Ac) and trimethylation of K4 (H3K4me3) are both chromatin marks that 
facilitate the formation of an “open” structure of chromatin that is conducive to increased access of TFs and 
induction of transcription35,36. We used ChIP to investigate the extent of H3Ac and H3K4me3 marking associ-
ated with the PRKCB promoter in CLL and normal B cells, focussing on the region of DNA containing the SP1 
binding sites (Fig. 4a and b). We found that these histone marks were present to a significantly greater extent with 
the PRKCB promoter in CLL cells compared to normal B cells. This suggests that increased access of SP1 to the 
PRKCB promoter in CLL cells compared to normal B cells is likely the result of histone relaxation due to permis-
sive epigenetic marking rather than changes in gene methylation.
VEGF induces PKCβ gene expression in CLL cells by stimulating SP1 and inhibiting STAT3 asso-
ciation with the PRKCB promoter sequence. Derepression of gene expression may also explain the high 
levels of PKCβ II in CLL cells, and in this respect a recent study demonstrated that active STAT3 can interact with 
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Figure 1. Mithramycin and SP1-specific siRNA reduce PKCβII mRNA and protein levels in CLL cells. 1 × 107 
CLL cells were cultured for 24 h in the presence of indicated concentrations of mithramycin (in nmol/L), or 
were nucleofected with the indicated SP1-specific or control siRNA oligonucleotides (Neg) and then cultured as 
described in the materials and methods. PKCβ II mRNA levels were then measured by qRT-PCR and are reported 
relative to RNApolII expression. (a) PKCβ II mRNA levels in CLL cells from a single patient. T0 indicates CLL 
cells used directly after thawing. UT indicates CLL cells cultured for 24 h. MIA indicates CLL cells cultured for 
24 h with the indicated concentrations of mithramycin (in nmol/L). The results show mean ± SE of n = 3 separate 
experiments. (b) Effect of 200 nM mithramycin on PKCβ II mRNA levels in CLL cells taken from 5 patients 
(mean ± SD). (c) Effect of SP1 siRNA compared to negative control siRNA (Neg) on primary CLL cells with 
respect to SP1 mRNA (mean ± SD of n = 4 experiments). (d) Effect of SP1 siRNA compared to negative control 
siRNA (Neg) on primary CLL cells with respect to PKCβ mRNA (mean ± SD of n = 3 experiments). (e) Western 
blot showing the effect of SP1 siRNA and negative control siRNA (Neg) on primary CLL cells with respect to SP1 
and PKCβ II protein levels (n = 1 experiment). Western blots (cropped images) were performed using 10 μ g  
of total cellular protein derived from CLL cell lysates. In Parts a and b mithramycin treatment had no effect on 
overall CLL cell viability. In Parts c and d, CLL cell viability was equivalent between control and SP1-specific 
siRNA treated cells. Statistical analysis for this figure was performed using a student’s t-test for paired data.
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the PRKCB promoter to suppress expression of this gene in myeloid cells23. We used ChIP to compare STAT3 
binding to the PRKCB promoter in CLL and normal B cells and we found no significant difference in overall 
association (Fig. 5a). However, there did seem to be greater variability in STAT3 binding between CLL cases, with 
some having quite high levels while others had very little. Interestingly, overnight culture of CLL cells resulted 
in a spontaneous increase in STAT3 association with the PRKCB promoter (Fig. 5b), and this corresponded with 
both an observed decrease in PRKCB promoter-associated SP1 (Figs 3b and 5c) and with the dynamics of PKCβ 
II mRNA levels in CLL cells cultured overnight (Figs 1b and 5d). To investigate this phenomenon we referred to 
previous work demonstrating VEGF-induction of PKCβ II expression in CLL cells24. Figure 5d confirms within 
the current study that addition of VEGF to cultures of CLL cells stimulates PKCβ II mRNA production, and 
Fig. 5c and b further demonstrate by ChIP analysis that the mechanism respectively involves enhancement of 
SP1 and repression of STAT3 binding to the PRKCB promoter. We confirmed that STAT3 operates as a repressor 
of PRKCB function in B lymphoid cells in experiments using a pGL3-pkcβ 1.2 kb construct containing reported 
STAT3 binding sites23. Similar to the findings of this group, we found that mutation of STAT3 binding site 1 or 
sites 2 plus 3 had no effect, whereas mutation of STAT3 binding site 4 resulted in significantly increased promoter 
activity (Supplementary Figure 2). Taken together, these results strongly suggest a dynamic relationship between 
gene expression mediated by SP1 and gene repression mediated by STAT3 in the control of PRKCB transcription 
in CLL cells that is regulated by the presence of VEGF.
Higher levels of SP1 expression in CLL cells likely contributes to overexpression of PKCβII. We 
next considered whether high levels of SP1 contributed to overexpressed PKCβ II in CLL cells. We found that SP1 
expression was significantly higher in CLL cells than in normal B cells (Fig. 6a), and that SP1 protein and mRNA 
Figure 2. PRKCB promoter-driven luciferase expression in MEC1 cells is mediated by SP1. 2 × 106 MEC1 
cells were transfected either with empty pGL3 and pRL (Emp), or with pGL3-pkcβ -0.5 and pRL (luc) according 
to the procedure outlined in the materials and methods. (a) Effect of mithramycin. Cells were cultured for 
24 h under serum-rich conditions, and then transferred into serum-free conditions for a further 48 h. For the 
final 24 h, 200 nM mithramycin (MIA) was added where indicated. (b) The effect of siRNA knockdown of SP1 
expression was performed by co-transfection of the cells with either control or SP1-specific siRNA as indicated. 
Following culture for 72 h, the cells were harvested and a luciferase assay was performed. (c) The effects of 
site directed mutagenesis of the SP1 binding sites in the PRKCB promoter was investigated. MEC1 cells were 
transfected with pGL3 (Emp), wt pGL3-pkcβ -0.5 (WT), or with pGL3-pkcβ -0.5 containing a mutation within 
the SP1 binding site 1 (Mut 1), site 2 (Mut 2) or site 1 and 2 (Mut 1 + 2). Luciferase assays were performed 
following 72 h culture of the cells under serum-rich conditions. In all parts of this figure the data presented 
represent mean ± SE of n = 3 replicate experiments. Statistical analysis was performed using a students t-test for 
paired data.
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levels correlated highly with PKCβ II mRNA expression within our local cohort of patient samples (Fig. 6b and c). 
Furthermore, reanalysis of gene expression profile data available for CLL cells within the Immuno-Navigator 
database37 also showed correlation between SP1 and PRKCB gene expression (Fig. 6d). Taken together, these data 
strongly suggest a direct relationship between SP1 and PRKCB gene expression in CLL cells.
Figure 3. SP1 binds to the PRKCB promoter sequence in CLL cells. ChIP analysis of SP1 binding to 
the PRKCB promoter. (a) CLL and normal B cell extracts from 5 × 106 cells were prepared and SP1 was 
immunoprecipitated. PRKCB promoter sequences associated with SP1 were detected by qPCR and are 
presented as fold enrichment compared to the PRKCB promoter sequences associated with the non-specific 
IgG immunoprecipitation control. The mean ± SD of these experiments is displayed. Statistical analysis was 
performed using a Mann-Whitney U-test. (b) 5 × 106 CLL cells were used either immediately after thawing 
(T0), or were incubated for 24 h in the absence (UT) or presence of 200 nM mithramycin (MIA). SP1 was 
immunoprecipitated from prepared extracts and the presence of the PRKCB promoter was detected using qPCR. 
The results are presented as fold enrichment of PRKCB promoter sequences associated with SP1 compared to the 
IgG immunoprecipitation control (IgG). The data presented represent mean ± SE of n = 3 replicate experiments 
using cells from the same patient. Statistical anlaysis was performed using a students t-test for paired data.
Sample ID B-CLL/Normal B % purity Mean % methylation
2649
Normal B
96.12 3.49
2667 97.12 2.22
2668 93.15 2.3
2675 — 1.73
2063
B-CLL
99.79 3.32
2064 — 4.51
2226 — 2.31
2262 93.03 1.05
2458 91.09 0.8
2536 99.33 3.16
Table 1.  PRKCB promoter methylation in normal B and CLL cells. Normal B and CLL cells were purified 
each from 5 healthy donors or CLL patients, respectively. Genomic DNA was isolated from these cells, and 
methylation of the PRKCB promoter was determined as described in the materials and methods. % methylation 
is reported as the mean average methylation of 8 CpGs within the analyzed sequence. Where a dash occurs 
within the % purity of the cells indicates where cell purity was not assessed following purification.
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Discussion
In this manuscript we describe the mechanism of VEGF-stimulated PKCβ gene expression on the transcriptional 
level. The results we present are the first to demonstrate a clear role for SP1 in the regulation of PKCβ II expression 
in CLL cells, and we suggest that access of SP1 to the promoter of PRKCB likely results both from a chromosome 
landscape that is permissive of gene transcription and from VEGF-mediated inhibition of the suppressive effects 
of STAT3. These findings are not only important to our understanding of the pathobiology of CLL cells, but may 
also be relevant for the microenvironmental stromal cells where CLL cells are reported to induce expression of 
PKCβ II38 and for the malignant cells of other neoplasms where PKCβ II is overexpressed12–15.
SP1 is a ubiquitous TF that binds GC-rich regions of target gene promoters and transcribes a variety of genes 
involved in cell cycle progression, differentiation, growth and apoptosis32. We have found that SP1 leads to tran-
scription of PRKCB, a finding that brings insight to previous studies characterising the basal promoter region of 
this gene18,19. Our findings confirm those of Hagiwara et al.22 who also use mithramycin and SP1-specific siRNA to 
investigate PKCβ expression in HeLa cells. However, our data provide further understanding by showing that SP1 
directly binds and induces transcription from the PKCβ gene promoter within primary CLL cells. Furthermore, 
our study also differs from the study by Hagiwara et al.22 because we find largely similar DNA methylation of 
the PRKCB promoter region containing SP1 binding sites in normal B compared to CLL cells, and this finding is 
supported by those of another study comparing the DNA methylome between normal B and CLL cells39. Instead, 
greater access of SP1 to the PRKCB promoter in CLL cells seems to be due to a different epigenetic mechanism. 
H3Ac and H3K4me3 are both euchromatin histone marks permissive of active gene expression35,36, and we show 
that these marks are associated to a greater extent with the PRKCB promoter in CLL cells than in normal B cells. 
Histone marks have not previously been investigated within the context of PKCβ gene regulation in CLL cells or 
other cell types, but are nevertheless important because of their role in determining chromatin structure and state 
of cellular differentiation. Recent reports suggest that expression of enzymes responsible for histone marking is 
Figure 4. The PRKCB promoter of CLL cells contains histone marks permissive of gene activation. Purified 
normal B cells and CLL cells were analysed by ChIP for H3Ac and H3K4me3 histone mark association with the 
promoter region of PRKCB upstream of the transcriptional start site. (a) Comparison of H3Ac histone mark 
association with PRKCB promoter in normal B and CLL cells. (b) Comparison of H3K4me3 histone mark 
association with PRKCB promoter in normal B and CLL cells. The results are presented as fold enrichment of 
PRKCB promoter sequences associated with H3Ac or H3K4me3 compared to the IgG immunoprecipitation 
control, and represent the mean ± SD using cells from different patients. Statistical analysis was performed 
using a Mann-Whitney U-test.
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deregulated in CLL, and may relate to disease prognosis and pathogenesis40–42. One consequence of this deregu-
lated expression may be the granting of greater access of SP1 to the promoter region of PRKCB.
Overexpression of PKCβ II in CLL cells is, at least, partially the result of concomitant increased expression 
of SP1. This conclusion is supported by observations by us and others43 that this TF is expressed at significantly 
higher levels in CLL cells than in normal B cells, and by our ability to correlate SP1 protein and mRNA levels 
with PKCβ mRNA levels in CLL cells. In particular, the relationship between SP1 and PKCβ mRNA expression is 
Figure 5. VEGF stimulates SP1 association with the PRKCB promoter sequence in CLL cells. 5 × 106 CLL 
cells were used directly (T0) or cultured overnight in the absence (UT) or presence of 100 ng/mL VEGF or 
200 nM mithramycin (MIA). (a) ChIP analysis of STAT3 association with the PRKCB promoter in CLL and 
normal B cells in individual samples. The mean ± SD of these experiments is displayed. Statistical analysis was 
performed using a Mann-Whitney U-test. (b) ChIP analysis of STAT3 association with the PRKCB promoter 
in CLL cells incubated overnight ± VEGF. (c) ChIP analysis of SP1 association with the PRKCB promoter using 
the same CLL samples as in part (b). IgG is the immunoprecipitation control. (d) qRT-PCR analysis of PKCβ II 
mRNA levels in CLL cells measured in comparison to RNApolII. For ChIP analyses PRKCB promoter sequences 
associated with STAT3/SP1 were detected by qPCR and are presented as fold enrichment compared to the 
PRKCB promoter sequences associated with the non-specific IgG immunoprecipitation control. In parts  
(b,c and d) the data presented represent the mean ± SE of n = 3 experiments using CLL cells from different 
patients. Statistical analysis was performed using a students t-test for paired data.
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strongly supported by our analysis of publicly-available gene expression profiles associated with CLL cells avail-
able through the Immuno-Navigator website37. Although correlation of SP1 with PRKCB expression does not 
mean that one affects the other, our demonstration that SP1 association with the PRKCB promoter correlates 
with decreased and increased gene expression strongly suggests that SP1 overexpression plays a distinct role in 
increased PKCβ expression in CLL cells. This finding therefore provides insight into observations of increased 
Figure 6. SP1 is overexpressed in CLL cells, and expression correlates with PRKCB transcription.  
(a) SP1 protein expression relative to β -actin was determined in lysates of purified normal B and CLL cells by 
Western blot analysis. 10 μ g of protein was used for each sample, and the ratio of SP1 to β -actin was determined 
following imaging of chemoluminescence. Statistical analysis was performed using a Mann-Whitney U-test. 
(b) Graph showing the relationship between SP1 protein expression and PKCβ mRNA levels, determined by 
qRT-PCR, in purified CLL cells. (c) Graph showing the relationship between SP1 and PKCβ mRNA levels, 
determined by qRT-PCR, in purified CLL cells. (d) Graph showing relationship between SP1 and PRKCB gene 
expression in CLL cells taken from publically-available data stored on the Immuno-Navigator database37.
www.nature.com/scientificreports/
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SP1 expression in other tumours such as those of the lung where it contributes to tumour progression, particu-
larly in early stages of the disease44, and where this TF likely also drives the increased levels of PKCβ expression 
that have been reported in these tumours45,46.
An additional factor contributing to overexpression of PKCβ II is suggested by our previous observation that 
VEGF stimulates PRKCB transcription in CLL cells24. The experiments presented within the current manuscript 
bring insight into the mechanism of how this happens, and provides a potential explanation for reported observa-
tions of overexpressed PKCβ II in tissue sections from B lymphoid malignancies13,47. We show that PKCβ II mRNA 
levels and SP1 association with the PRKCB promoter decrease with overnight culture of CLL cells, and that this 
is coupled with an increased association of STAT3. When VEGF is present in CLL-cell cultures, SP1 association 
with the PRKCB promoter is maintained/stimulated whilst STAT3 association remains low or is suppressed. This 
mechanism is likely to involve active PKCβ II because of our previous work demonstrating that pretreatment of 
CLL cells with LY379196, a PKCβ -specific inhibitor48, blocks the effects of VEGF24. That STAT3 is able to interact 
with the PRKCB promoter in CLL cells is supported by studies showing constitutive activation of this protein49,50. 
Taken together, these observations potentially explain how active PKCβ II regulates its own gene expression25,26, 
and also link SP1 and STAT3 into the pathobiology of CLL because high levels of VEGF are present in lymph 
nodes and bone marrow of CLL patients with late stage disease28.
Other TFs reported to regulate PRKCB transcription include MITF and RUNX120,21, but these TFs are likely 
less important than SP1 in regulating PKCβ expression in CLL cells. Direct binding of MITF to the PRKCB pro-
moter has not been demonstrated, and it is proposed that this TF acts as a co-activator20. With respect to RUNX1, 
ChIP analysis has demonstrated binding of this TF to the PRKCB promoter but mutation of the RUNX1 binding 
site within this promoter only partially inhibits transcription of the gene21. The experiments using site-directed 
mutagenesis of the SP1 binding sites to completely block gene expression driven by this promoter suggests that 
basal transcription of PRKCB requires SP1 but not RUNX1. It is possible that RUNX1 may cooperate with SP1 to 
promote PKCβ gene expression in CLL cells because SP1 is shown to interact with the DNA binding domain of 
RUNX1 to facilitate expression of other genes in other cell types51. Whether this is the case in CLL and PRKCB 
will require further experiments using larger promoter constructs.
A potential limitation of our study is the use of fold enrichment to normalise the data obtained from the ChIP 
experiments. This technique of normalisation is open to variation between primer sets, samples and experiments 
as described by Haring et al.52. However, we believe our experimental approach limited these potential influ-
ences. Our experiments using mithramycin are robust because we observed that this agent effectively displaced 
SP1 from its binding sites within the proximal promoter of PRKCB both in MEC1 and in primary CLL cells, 
an observation consistent with reported effects of this drug on this22 and other genes29,30. Moreover, potential 
inter-experimental variance was reduced by performing each ChIP experiment on all CLL cell samples in one go. 
Although each patient sample was slightly different, variation in SP1/STAT3 binding was observed to be consist-
ent with variation in PKCβ mRNA levels, particularly with respect to cells incubated ± VEGF.
In conclusion, this is the first paper to demonstrate a clear role for SP1 in PRKCB transcription, and further 
link this TF into the pathobiology of CLL cells. Because of the myriad of genes that are potentially transcribed by 
SP132, future work identifying the mechanism(s) controlling SP1 interaction with the promoter region of PRKCB, 
particularly with respect to how STAT3 may regulate this interaction, will not only be important for understand-
ing how this gene is regulated in the malignant cells of CLL and other diseases where PKCβ is overexpressed, but 
may also add important insight into the regulation of other genes important to the pathobiology of these diseases.
Methods
Cell culture. CLL cells were obtained from the peripheral blood taken from patients with informed consent 
and with the approval of the Liverpool Research Ethics Committee. Stored CLL cell samples from the Liverpool 
Leukaemia Biobank were prepared using a standard protocol as described previously53, and had a minimum 
viability of 80%. CLL sample usage and performed experiments on these samples were recorded in compliance 
with a Research Ethics Agreement overseen by the University of Liverpool and Royal Liverpool and Broadgreen 
NHS University Hospital Trust.
MEC-1 cells were obtained from the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell 
Cultures (Braunschweig, Germany) and cultured in Dulbecco’s Modified Eagle Medium (DMEM). Mithramycin 
was purchased from Sigma-Aldrich (Gillingham, U.K.).
Quantitative reverse transcriptase PCR. ZR-RNA™ MiniPrep kits (Zymo Research, Cambridge 
Bioscience Ltd, Cambridge U.K.) were used to isolate total RNA, which was then quantified using a Nanodrop 
2000C spectrophotometer (NanoDrop Products Wilmington, DE, USA). cDNA was generated using 1 μ g of RNA 
with an oligo-dT primer and Moloney murine leukemia virus reverse transcriptase (Promega, Southampton, UK). 
PCR primers were purchased from Eurofins (MWG Operon, Ebersberg, Germany) and are listed in Table 2. 
Reactions were carried out using Hot Fire pol EvaGreen qPCR mastermix (Newmarket Scientific Ltd, U.K.) on a 
Stratagene MX3000P PCR machine with the following cycle conditions: 10 min at 95 °C then 40 cycles of 30 sec 
at 95 °C, 20 s at 58 °C (PKCβ II) or 64 °C (SP1), 30 s at 72 °C and 11 s at 81 °C (PKCβ II) or 80 °C (SP1) to collect 
fluorescence data. Melt curve analysis was performed to assess purity of the amplified products. Reactions were 
normalised to RP2 and relative expression determined using the ∆ ∆ Ct method.
DNA methylation analysis. Purified normal B and CLL cells were isolated using anti-CD19 magnetic 
MicroBeads and the MiniMacs system according to the manufacturer’s instructions (Miltenyi Biotech Ltd, Bisley, 
UK). Cell purity was assessed by flow cytometry using CD20-PE antibodies (BD Biosciences, UK), and sam-
ples with populations > 90% CD20+ cells were considered to be of sufficient purity for subsequent experiments. 
www.nature.com/scientificreports/
1 0Scientific RepoRts | 7:43228 | DOI: 10.1038/srep43228
Genomic DNA from purified cells was extracted using a Promega Wizard genomic DNA extraction kit (Promega, 
Madison, WI, USA). 1 μ g of genomic DNA was sodium bisulphite treated using a EZ-DNA methylation gold 
kit (Zymo Research, Irvine, CA, USA). A CpG-rich target region within the PRKCB promoter was selected for 
interrogation, and forward, reverse and pyrosequencing primers designed using Pyromark Assay Design 2.0 
software (Qiagen, Valencia, CA, USA) and synthesized by Eurofins MWG Operon (Table 2). PCR amplification 
was performed using 400 μ M forward and reverse primers, 60 ng bisulphite-treated DNA, 200 μ M dNTPs, 1 mM 
MgCl2 and 1.25 U GoTaq Flexi DNA polymerase (Promega, Madison, WI, USA). PCR cycling conditions were as 
follows: 94 °C for 3 min, followed by 40 cycles of 94 °C for 30 s, 50 °C for 30 s and 72 °C for 30 s and an additional 
72 °C extension for 10 min. Specific PCR product quality and quantity were confirmed by agarose gel electro-
phoresis. PCR products were then immobilized on to streptavidin sepharose beads (GE Healthcare Biosciences, 
Pittsburgh, PA, USA) and sequentially washed in 70% ethanol, 0.2 M NaOH and 10 mM Tris acetate, pH 7.5, 
using a PSQ96 Vacuum Workstation (Qiagen, Valencia, CA, USA). PRCKBmeth_seq primer was then hybridized 
to the retained biotinylated DNA strand in annealing buffer and analyzed using PSQ96 MA Pyrosequencer and 
PyroMark Gold Q96 reagents (Qiagen, Valencia, CA, USA). Results presented as % methylation represent the 
mean average methylation of 8 CpGs within the analyzed sequence.
Nucleofection and luciferase assays. All cell transfections were performed using an Amaxa nucleofector 
(Lonza Biologics plc, Tewkesbury UK). MEC-1 cells were transfected using solution V and programme X-01. A 
plasmid (pGL3-pkcβ -0.5) containing 500 bp of the proximal promoter of PRKCB cloned upstream of the firefly 
luciferase was kindly provided by Dr A P Fields (Mayo Clinic College of Medicine, Jacksonville, Florida, USA)26. 
Plasmids wt-pGL3-pkcβ -1.2 kb and site 1, site 2 + 3, or site 4 mutants of the STAT3 binding sites within the 
PRKCB promoter of pGL3-pkcβ -1.2 kb were prepared as described23. MEC-1 (2 × 106 cells/ml) were co- trans-
fected with 2 μ g of pGL3-pkcβ -0.5 and 100ng of pRL Renilla luciferase control plasmid (Promega, UK) to allow 
for normalisation of transfection efficiency. In some experiments SP1-specific siRNA duplexes were also included 
(see below). Firefly and Renilla luciferase activity was measured using a Dual-Luciferase Reporter Assay kit 
(Promega, UK), and luciferase activity of the former is reported relative to that the latter.
siRNA knockdown of SP1. siRNA (TriFECTa® RNAi, Integrated DNA Technologies, Glasgow U.K.) was 
used to knockdown expression of SP1 in CLL, MEC-1 and Daudi cells at a final concentration of 2 μ M. The 
sequences for the SP1-specific siRNA oligonucleotide duplexes are displayed in Table 2. Twenty four hours after 
transfection, cells were washed once with PBS and incubated for 24 hours in serum rich media, which was then 
replaced with serum free media and incubation for a further 48 hours. Knockdown of SP1 expression was con-
firmed by Western blot and qRT-PCR analysis.
qRT PCR Primers
PKCβII Forward 5′ -TGGGGTGACACCCAAGACATTC-3'
Reverse 5′ -GCTGGATCTCTTTGCGTTCAAG-3'
SP1 Forward 5′ -GACGTTGATGCCACTGTTGGCAAG-3'
Reverse 5′ -TCAAGACCCACCAGAATAAGAAGGGAG-3'
RNA polymerase II 
(RP2) Forward 5′ -CAAGACTGCTGAGACTGGATAC-3'
Reverse 5′ -CAAAGCGGAACTTCTTCTCAAAAG-3'
DNA methylation Primers
PRKCBmeth Forward 5′ -GTTTGGGTATATTTTTTGAA-3'
Reverse 5′ -Biotin-CCCTCCTCATTTACATC-3'
Sequence 5′ -TTGGGTATATTTTTTGAA-3'
Site-Directed Mutagenesis Primers
SP1 m1 Forward 5′ -AGCAGCTGGCAGCGCTATGCTAGGCCTGGGCGCG-3'
Reverse 5′ -CGCGCCCAGGCCTAGCATAGCGCTGCCAGCTGCT-3'
SP1 m2 Forward 5′ -TGGGCGCGATGCAAATGAGGAATGCTAGGCTGGCCCGGG-3'
Reverse 5′ -CCCGGGCCAGCCTAGCATTCCTAGCATTCCTCATTTGCATCGCGCCCA-3'
ChIP Primers
PRKCB prom Forward 5′ -GCACGCTTAGCCGCGAGG-3'
Reverse 5′ -AGCTGCTGCCGCTCGTCC-3'
siRNA oligos
Duplex 1 Sense 5′ -CCAAGGAAAUAAGGACAGUCUAGCT-3'
Antisense 3′ - AUGGUUCCUUUAUUCCU-GUCAGAUCGA-5'
Duplex 2 Sense 5′ -CCCUCAACCCUAUUCAUUAGCAUTA-3'
Antisense 3′ -AUGGGAGUUGGGAUAAGUAAUCGUAAU-5'
Duplex 3 Sense 5′ -GUGCAAACCAACAG-AUUAUCACAA-3'
Antisense 3′ - GUCCACGUUUGGUUGUCUAAUAGUGUU-5'
Table 2.  Sequences of DNA oligonucleotides used.
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Site-directed mutagenesis. Site-directed mutagenesis of the SP1 binding sites within the PRKCB promoter 
sequence was carried out using a Stratagene QuickChange Site-Directed Mutagenesis kit (Agilent Technologies, 
Stockport, UK) according to manufacturer’s instructions. The primers used for introducing the mutations were 
all from Eurofins MWG Operon (Table 2). Introduced mutations were verified by commercial sequencing (Source 
BioScience plc, Nottingham, UK).
Chromatin immunoprecipitation (ChIP) analysis. Cells (5 × 106) were washed with PBS and then 
treated with 0.5% formaldehyde for 5 min at room temperature to cross link proteins and DNA. The reaction 
was stopped with 135 mM glycine for 5 min at room temperature. Following washing with cold PBS, cells were 
lysed with 1 ml cold lysis buffer (10 mM Tris-HCl pH 7.4, 10 mM NaCl, 5 mM MgCl2, 0.2% NP-40 plus protease 
and phosphatase inhibitors) on ice for 15 min. Nuclei were isolated by centrifugation at 500 g for 5 min (4 °C), 
resuspended in 500 μ l of cold MNase buffer (0.3 M sucrose, 10 mM Tris-HCl pH 7.4, 15 mM NaCl, 60 mM KCl, 
5 mM MgCl2, 3 mM CaCl2, 0.5 mM spermidine, 0.15 mM spermine) to which 125 U micrococcal nuclease was 
added and then incubated for 20 min at 37 °C. The reaction stopped by the addition of EDTA to a final concentra-
tion of 10 mM. NP-40, sodium deoxycholate and SDS were added to final concentrations of 1%, 0.5% and 0.1% 
SDS respectively. Nuclei were disrupted by sonication to release fragmented chromatin and insoluble material 
removed by centrifugation at 12000 × g for 5 min (4 °C). Protein/DNA complexes were precipitated overnight at 
4 °C using 5 μ g ChIP-grade antibody and 20 μ l Magna ChIP protein A + G magnetic beads (Millipore, Watford, 
UK). Following extensive washing, beads were resuspended in elution buffer (1% SDS, 0.1 M NaHCO3, 0.2 M 
NaCl, 10 μ g proteinase K) and incubated at 65 °C for 2 h to reverse cross links. Eluted DNA was purified using a 
DNA clean and concentrator-5 kit (Cambridge Bioscience Ltd, UK). One microlitre of the purified DNA was used 
for PCR amplification using PRKCB promoter specific primers (Table 2). Cycle conditions were 20 s at 95 °C then 
40 cycles of 20 s at 56 °C, 30 s at 72 °C and 11 s at 85 °C to collect fluorescence data.
Gene expression profile (GEP) analysis. Publicly available GEP data for SP1 and PRKCB expres-
sion in CLL cells was analysed using the Immuno-Navigator website (http://sysimm.ifrec.osakau. ac.jp/
immuno-navigator)37. Jetset (http://www.cbs.dtu.dk/biotools/jetset/)54 was employed to select reliable 
probes for SP1 and PRKCB from the Affymetrix hgu133plus2 chip used to construct the GEP data. Pearson’s 
product-moment correlation analysis was performed using GraphPad Prism™ software.
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